Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

By LabMedica International staff writers
Posted on 20 Sep 2023

Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in the European Union (EU) market.

Tasso, Inc.’s (Seattle, WA, USA) Tasso+ device is intended for single-use and is capable of obtaining microliter amounts of capillary whole blood. What sets Tasso+ apart is its virtually pain-free and user-friendly design, along with groundbreaking technology, which enhances user satisfaction. This makes it ideal for remote blood collection, particularly in decentralized clinical trials run by pharmaceutical companies, focusing on pharmacokinetic and biomarker research.

Tasso+ offers a patient-friendly approach to blood collection that helps break down access barriers, allowing patient groups who are typically underserved or understudied to take part in clinical trials. Beyond research, healthcare providers can also use the device to assess blood chemistries, thus expanding care accessibility. The device had previously received Class II 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2022. With the new CE Mark, Tasso+ has become the first device in its category to get full clearance both in the U.S. and the EU.

“This designation is an important milestone for Tasso, allowing us to build upon the success of our CE Marked Tasso-M20 device and continue to expand our commercial footprint and reduce healthcare access barriers in Europe, where demand increasingly grows for patient-centric solutions,” said Ben Casavant, PhD, CEO and co-founder of Tasso. “The Tasso+ CE Mark enables us to support the pharmaceutical industry, academic and government institutions on research and clinical initiatives, as well as accelerate access to remote testing and care for more patient populations. We are excited to expand our customer base in Europe.”

Related Links:
Tasso, Inc.